References:
- Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, et al.
Baseline characteristics, management practices, and in-hospital
outcomes of patients hospitalized with acute coronary syndromes in the
Global Registry of Acute Coronary Events (GRACE). The American journal
of cardiology. 2002;90(4):358-63.
- Ralapanawa U and Sivakanesan R. Epidemiology and the Magnitude of
Coronary Artery Disease and Acute Coronary Syndrome: A Narrative
Review. J Epidemiol Glob Health. 2021 Jun; 11(2): 169–177.
- Doost Hosseiny A, Moloi S, Chandrasekhar J, et al. Mortality pattern
and cause of death in a long-term follow-up of patients with STEMI
treated with primary PCI. Open Heart. 2016;3:e000405.
- Van ’t Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of
12-lead electrocardiogram after successful reperfusion therapy for
acute myocardial infarction. Zwolle Myocardial infarction Study Group.
Lancet (London, England). 1997;350(9078):615-9.
- Van ’t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ,
Zijlstra F. Angiographic assessment of myocardial reperfusion in
patients treated with primary angioplasty for acute myocardial
infarction: myocardial blush grade. Zwolle Myocardial Infarction Study
Group. Circulation. 1998;97(23):2302-6.
- Topol EJ, Yadav JS. Recognition of the importance of embolization in
atherosclerotic vascular disease. Circulation. 2000;101(5):570-80.
- Eisenberg PR, Ghigliotti G. Platelet-dependent and procoagulant
mechanisms in arterial thrombosis. International Journal of
Cardiology. 1999;68, Supplement 1:S3-S10.
- Zeymer U. The role of eptifibatide in patients undergoing percutaneous
coronary intervention. Expert Opinion on Pharmacotherapy.
2007;8(8):1147-54.
- Borja Ibanez et al. 2017 ESC Guidelines for the management of acute
myocardial infarction in patients presenting with ST-segment
elevation: The Task Force for the management of acute myocardial
infarction in patients presenting with ST-segment elevation of the
European Society of Cardiology (ESC). Eur Heart J. 2018 Jan
7;39(2):119-177.
- Jennifer S. Lawton. 2021 ACC/AHA/SCAI Guideline for Coronary Artery
Revascularization: A Report of the American College of
Cardiology/American Heart Association Joint Committee on Clinical
Practice Guidelines. Circulation. 2022;145:e18–e114.
- De Lemos JA, Gibson CM, Antman EM, Murphy SA, Morrow DA, Schuhwerk KC,
et al. Abciximab and early adjunctive percutaneous coronary
intervention are associated with improved ST-segment resolution after
thrombolysis: Observations from the TIMI 14 Trial. American heart
journal. 2001;141(4):592-8.
- Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria
AN. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow
after coronary reperfusion. A quantitative myocardial contrast
echocardiography study. J Am Coll Cardiol. 2004;43(2):276-83.
- Shariati H, Sanei H, Pourmoghadas A, Salehizadeh L, Amirpour A.
Immediate outcomes of eptifibatide therapy during intracoronary stent
implantation. Advanced Biomedical Research. 2016;5:204.
- Topcu S, Karal H, Kaya A, Bakirci EM, Tanboga IH, Kurt M, et al. The
safety and efficacy of 12 versus 24 hours of tirofiban infusion in
patients undergoing primary percutaneous coronary intervention.
Clinical and applied thrombosis/hemostasis : official journal of the
International Academy of Clinical and Applied Thrombosis/Hemostasis.
2015;21(8):783-9.
- Schneider DJ. Anti-platelet therapy: glycoprotein IIb-IIIa
antagonists. British Journal of Clinical Pharmacology.
2011;72(4):672-82.
- Becker RC. Thrombosis and the role of the platelet. The American
Journal of Cardiology. 1999;83(9, Supplement 1):3-6.
- Mehran R et al. Standardized Bleeding Definitions for Cardiovascular
Clinical Trials. A Consensus Report From the Bleeding Academic
Research Consortium. Circulation. 2011;123:2736-2747.
- Joshua M. Stolker et al. Repeat Revascularization After Contemporary
Percutaneous Coronary Intervention. An Evaluation of Staged, Target
Lesion, and Other Unplanned Revascularization Procedures During the
First Year. Circ Cardiovasc Interv. 2012;5:772-782.
- Montalescot G et al. Abciximab in primary coronary stenting of
ST-elevation myocardial infarction: a European meta-analysis on
individual patients’ data with long-term follow-up. European Heart
Journal (2007) 28, 443–449.
- Kandzari DE et al. Improved clinical outcomes with abciximab therapy
in acute myocardial infarction: a systematic overview of randomized
clinical trials. Am Heart J. 2004 Mar;147(3):457-62.
- Jeremias A et al. Impact of Abciximab on Mortality and Reinfarction in
Patients with Acute ST-Segment Elevation Myocardial Infarction Treated
with Primary Stenting. Catheterization and Cardiovascular
Interventions. (2010) 75(6):895–902.
- Mehilli J et al. Abciximab in Patients with Acute
ST-Segment–Elevation Myocardial Infarction Undergoing Primary
Percutaneous Coronary Intervention After Clopidogrel Loading: A
Randomized Double-Blind Trial. Circulation. 2009;119:1933-1940.
- Zeymer U et al. Randomized comparison of eptifibatide versus abciximab
in primary percutaneous coronary intervention in patients with acute
ST-segment elevation myocardial infarction: results of the EVA-AMI
Trial. J Am Coll Cardiol. 2010 Aug 3;56(6):463-9.
- Tcheng JE et al. Novel dosing regimen of eptifibatide in planned
coronary stent implantation (ESPRIT): a randomised, placebo-controlled
trial. Lancet. 2000 Dec 16;356(9247):2037-44.
- Mahmoudi M et al. Integrilin in Patients Undergoing Primary
Percutaneous Coronary Intervention for ST-Elevation Myocardial
Infarction. J Interven Cardiol. 2011;24:351–356.
- Le May MR et al. Primary Percutaneous Coronary Angioplasty with and
Without Eptifibatide in ST-Segment Elevation Myocardial Infarction: A
Safety and Efficacy Study of Integrilin-Facilitated Versus Primary
Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial
Infarction (ASSIST). Circ Cardiovasc Intervent. 2009;2:330-338.
Table 1. Patients’ demographics and clinical characteristics.